BioSpace News Archive

Feb. 24, 2020 13:30 UTC – Updated data from the Phase 1 study in healthy subjects show that MGTA-145, in combination with plerixafor, met all primary and secondary endpoints – – Median of 4.1 million CD34+ cells/kg collected in a single day from eight subjects – – Magenta plans to initiate multiple Phase 2 studies in 2020, in both allogeneic and autologous transplant settings – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Magenta Therapeutics (NASDAQ: MGTA), a clinical

Feb. 24, 2020 13:55 UTC IRVINE, Calif.--( BUSINESS WIRE )-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “Existing Notes”), pursuant to which these investors exchanged an aggregate of approximately $11.0 million of the Existing Notes plus accrued inte

Positive Data on Many Medtronic Innovations Presented at ATTD: Extended Wear Infusion Set Designed to Last Twice as Long, MiniMed™ 670G System Real-Life Performance in Europe, and ProCGM Use in Type 2 Diabetes Patients

SUZHOU, China and ROCKVILLE, MD ., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has received approval from Center of Drug Evaluation (CDE), China NMPA, for the Phase Ib/I

NeuroScience Associates (NSA Labs) and Aiforia are bringing together their respective expertise in neuroscience and artificial intelligence (AI).

Innovative Forensic DNA has selected Intermountain Forensics as their lab services provider. Intermountain Forensics is the country’s first nonprofit forensic DNA lab, dedicated to bridging the gap between public and private labs.

Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically-meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status - The application is being reviewed under the FDA’s Real-Time Oncology Review pilot program LONDON , Feb. 24, 2020 /PRNewswire/ -- GlaxoSmithKline plc today

Eurofins DiscoverX announces partnership with VelaLabs through their Certified CRO Program for PathHunter® Bioassays that will enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions

Feb. 24, 2020 14:00 UTC Long-term HIV Infection Can lead to Inflammatory Abnormalities Such as Cardiovascular Disease BALTIMORE--( BUSINESS WIRE )-- On February 1, the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and OncoImmune, Inc. launched a new Phase II clinical trial called CALIBER, which will test whether OncoImmune’s lead product, CD24Fc, can reduce late effects of HIV infection, such as inflammatory abnormalities inc

Ljubljana, Slovenia, Feb. 24, 2020 (GLOBE NEWSWIRE) -- RAFARMA PHARMACEUTICALS INC. “ OTC:(RAFA)” is pleased to inform its shareholders that the previously-announced specialized research project between Rafarma and Khon Kaen University officially commenced on February 19, 2020. In a meeting at the University, Rafarma discussed entering the Thai market and implemented certain changes in the research planned for the next two years. Rafarma and MTP MATERIAL CO. LTD. Have formulated a plan to be